Targeting K-Ras has a long tradition in pancreatic cancer research; however, agents have struggled to progress from the laboratory into clinical practice, and recent progress with KRAS-G12C inhibitors offers potential; moreover, these have been licensed in the treatment of lung cancer but not yet pancreatic cancer [19]. This evidence concerns the gene KRAS and lung carcinoma.